Brickell Biotech to Participate at William Blair’s Biotech Focus Conference 2021
Get Alerts BBI Hot Sheet
Join SI Premium – FREE
BOULDER, Colo., July 06, 2021 (GLOBE NEWSWIRE) -- Brickell Biotech, Inc. (“Brickell”) (Nasdaq: BBI), a clinical-stage pharmaceutical company focused on developing innovative and differentiated prescription therapeutics for the treatment of debilitating skin diseases, today announced that its management team will participate in one-on-one investor meetings at the upcoming William Blair Biotech Focus Conference 2021, taking place virtually July 14 - 15.
About BrickellBrickell Biotech, Inc. is a clinical-stage pharmaceutical company focused on the development of innovative and differentiated prescription therapeutics for debilitating skin diseases with a focus on its lead asset sofpironium bromide for the treatment of hyperhidrosis. Brickell’s executive management team and board of directors bring extensive experience in product development and global commercialization, having served in leadership roles at large global pharmaceutical companies and biotechs that have developed and/or launched successful products, including several that were first-in-class and/or achieved iconic status, such as Cialis®, Taltz®, Gemzar®, Prozac®, Cymbalta® and Juvederm®. Brickell’s strategy is to leverage this experience to in-license, acquire, develop and commercialize innovative and differentiated pharmaceutical products that Brickell believes can be successful in the marketplace and transform lives by solving currently unmet patient needs. For more information, visit https://www.brickellbio.com.
Brickell Investor Contact:Dan FerryLifeSci Advisors(617) 430-7576[email protected]
Source: Brickell Biotech, Inc.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Cannabix Technologies Deploys BreathLogix Alcohol System at Montana's Big Horn County Probation and Pre-Trial Services Department Under State's 24/7 Sobriety Program
- Expressable Joins Amazon's Health Benefits Connector as its First Provider of Speech Therapy Services
- Sonor Investments Limited Announces Intention to Redeem First Preference Shares
Create E-mail Alert Related Categories
Globe Newswire, Press ReleasesRelated Entities
William Blair, BRIC, Definitive AgreementSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!



Tweet
Share